

Precision Treatment

Now you can identify RA patients who are unlikely to respond to TNF inhibitor (TNFi) therapy, BEFORE you prescribe

Step Forward


prism/RA™
Step Forward
MOLECULAR SIGNATURE TEST

Note: Response is defined as ACR50 or better

prism/RATM

Step Forward

MOLECULAR SIGNATURE TEST



Know whether response to TNF inhibitor (TNFi) therapy is unlikely—before you prescribe

The PrismRA® test is a first-of-its-kind **that provides**
objective, science-based guidance for RA therapy selection

- Improves overall patient response rate by up to 40% across all first-line treatments¹
- Lets you avoid wasted time and leverage the window when intervention is most impactful²
- Helps avoid unnecessary costs and exposure to drugs unlikely to provide adequate therapeutic effect

Note: Response is defined as ACR50 or better

1. Mellors TW, Withers JW, Ameli A, et al. Clinical validation of a blood-based predictive test for stratification of response to tumor necrosis factor inhibitor therapies in rheumatoid arthritis patients. *Netw Syst Med*. 2020;3(1):1-14.

2. Jamal S, Patra K, Keystone EC. Adalimumab response in patients with early versus established rheumatoid arthritis: DE019 randomized controlled trial subanalysis. *Clin Rheumatol*. 2009;28(4):413-419. doi:10.1007/s10067-008-1064-0

Actionable results to inform your treatment decisions

Use the PrismRA® test to identify a patient's likelihood of inadequate response to TNF inhibitor (TNFi) therapy. Results are reported on a continuous, 25-point scale, divided into four tiers to assist providers with interpretation.

Even patients with similar clinical presentations can vary widely in their likelihood of response to TNFi therapy.

Case Study

Two similar female patients failed conventional DMARDs for 3 consecutive months and are initiating their first targeted therapy.



Mary

Age: 57
Time since Dx: 1 year



Sarah

Age: 57
Time since Dx: 4 years

On methotrexate	Yes	Yes
Anti-CCP	Negative	Negative
Rheumatoid factor	Negative	Positive
C-reactive protein	0.78	3.63
Swollen joint count	8	8
Tender joint count	15	12
Physician global	50	43

Reflects actual patients from validation study

PrismRA[®]

Evidence-based therapy selection

The PrismRA test was studied in 300+ RA patients enrolled in the Consortium of Rheumatology Researchers of North America (CORRONA) Comparative Effectiveness Registry to Study Therapies for Arthritis and Inflammatory Conditions (CERTAIN) study.¹

- Specimen collected prior to starting initial targeted RA therapy
- Response defined as an ACR50 score at 6 months post TNF inhibitor (TNFi) therapy initiation
- Actual patient outcomes at 6 months were cross-referenced with PrismRA results
- Validation study (n=175) established the _____ and
- Components of the _____ were determined based on achievement of ACR50 score

Note: Response is defined as ACR50 or better

1. Mellors TW, Withers JW, Ameli A, et al. Clinical validation of a blood-based predictive test for stratification of response to tumor necrosis factor inhibitor therapies in rheumatoid arthritis patients. *Netw Syst Med.* 2020;3(1):1-14.

2. Data on file. Scipher Medicine, 2020.

Incorporating PrismRA® into your practice

Getting started is simple:



Request PrismRA
test kits from your
representative



[Click for form](#)




[Click for instruction sheet](#)



[Click for sample result](#)

Before you start a patient on a targeted biologic, let the PrismRA test help inform your choice.



Step Forward with PrismRA®

Incorporate the PrismRA test into your practice

Contact

If you are interested in learning more about PrismRA or want to bring the test into your practice, please contact the Scipher Medicine Provider Relations team via phone call, email or contact form.

855-724-7437 | support@prismra.com |



SA-0001Jul20

©2020 Scipher Medicine Corporation. All rights reserved.

Scipher Medicine and PrismRA are trademarks of Scipher Medicine Corporation.

